6 Genome Sequencing Stocks to Buy for Big Health-Care Profits

Genome sequencing - basically figuring out the order of DNA, the building blocks of life - was once essentially little more than a lab exercise. But now, it has reached commercial viability and then some.

The field of genomics goes back to the 1950s, though it really started in earnest with the start of the Human Genome Project in 1990 - a 13-year, $2.7 billion enterprise that was completed in April 2013.

Genome sequencing, in which scientists and their myriad machines detail the entire set of human DNA, has fantastic medical potential, allowing researchers to find genetic mutations - errors that can be harmless at times, but other times debilitating or even fatal. Moreover, genome sequencing is starting to reach realistic pricing - the costs have fallen down to about $1,000 at the low end, and companies are racing to cash in on the